1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Arthritis - Pipeline Review, H1 2014

Arthritis - Pipeline Review, H1 2014

  • February 2014
  • -
  • Global Markets Direct
  • -
  • 175 pages

Arthritis - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Arthritis - Pipeline Review, H1 2014’, provides an overview of the Arthritis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arthritis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Arthritis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Arthritis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Arthritis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Arthritis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Arthritis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Arthritis - Pipeline Review, H1 2014
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Arthritis Overview 9
Therapeutics Development 10
Pipeline Products for Arthritis - Overview 10
Pipeline Products for Arthritis - Comparative Analysis 11
Arthritis - Therapeutics under Development by Companies 12
Arthritis - Therapeutics under Investigation by Universities/Institutes 16
Arthritis - Pipeline Products Glance 18
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Arthritis - Products under Development by Companies 21
Arthritis - Products under Investigation by Universities/Institutes 24
Arthritis - Companies Involved in Therapeutics Development 25
Bristol-Myers Squibb Company 25
AstraZeneca PLC 26
GlaxoSmithKline plc 27
Taisho Pharmaceutical Co., Ltd. 28
Sylentis S.A. 29
Astellas Pharma Inc. 30
Eisai Co., Ltd. 31
Elan Corporation, plc 32
Teva Pharmaceutical Industries Limited 33
TheraKine Ltd. 34
Bone Medical Limited 35
Can-Fite BioPharma Ltd. 36
MEI Pharma, Inc. 37
Lexicon Pharmaceuticals, Inc. 38
CSL Limited 39
WhanIn Pharmaceutical Co., Ltd. 40
Oscotec Inc. 41
Viron Therapeutics, Inc. 42
PLx Pharma Inc. 43
Endocyte, Inc. 44
Taiwan Liposome Company, Ltd. 45
NasVax Ltd. 46
Georgia Tech Research Corporation 47
CalciMedica, Inc. 48
Zyngenia, Inc. 49
SelectX Pharmaceuticals, Inc. 50
AngioLab, Inc. 51
DoNatur GmbH 52
PharmaIN Corporation 53
CellAct Pharma GmbH 54
LegoChem Biosciences, Inc 55
Ampio Pharmaceuticals, Inc. 56
Inbiopro Solutions Pvt. Ltd. 57
Sagene Pharmaceuticals, Inc. 58
AnaMar AB 59
vida therapeutics inc. 60
Aurinia Pharmaceuticals Inc. 61
Dong-A Socio Holdings Co Ltd 62
Arthritis - Therapeutics Assessment 63
Assessment by Monotherapy Products 63
Assessment by Combination Products 64
Assessment by Target 65
Assessment by Mechanism of Action 69
Assessment by Route of Administration 73
Assessment by Molecule Type 75
Drug Profiles 78
laquinimod sodium - Drug Profile 78
PL-1100 - Drug Profile 80
MCS-18 - Drug Profile 81
GLPG-0555 - Drug Profile 83
CSL-324 - Drug Profile 85
VT-346 - Drug Profile 86
CF-602 - Drug Profile 87
PL-5100 - Drug Profile 88
EC-1496 - Drug Profile 89
AMAP-102 - Drug Profile 90
DIS-BIO-OA01 - Drug Profile 92
Anti-CD3 Oral Immunotherapy - Drug Profile 93
BN-005 - Drug Profile 95
BN-008 - Drug Profile 96
Ampion - Drug Profile 97
PGC-VIP - Drug Profile 99
selegiline + NSAIDs - Drug Profile 100
AS-1940477 - Drug Profile 101
dexamethasone acetate - Drug Profile 102
MDC-917 - Drug Profile 103
Metalloproteinase Inhibitors - Drug Profile 104
CAP-2.1 - Drug Profile 105
CAP-2.2 - Drug Profile 106
CAP1.1 - Drug Profile 107
PWT-143 - Drug Profile 108
AR-C-102222 - Drug Profile 109
Tumor Necrosis Factor Receptor-Hybrid Fc - Drug Profile 110
Small Molecules to Inhibit C-Rel for Central Nervous System, Musculoskeletal, Respiratory and Metabolic Disorders - Drug Profile 111
Intracellular IL-1 Receptor Antagonist - Drug Profile 112
Pegylated Arginine Deiminase - Drug Profile 113
Sphingosine-1-Phosphate Agonists - Drug Profile 114
DCB-3503 - Drug Profile 115
AT-132 - Drug Profile 116
Peptidyl Allyl Sulfones - Drug Profile 117
TASP-0415914 - Drug Profile 118
fluticasone propionate - Drug Profile 119
Bi-Specific Anti-TNFalpha/Ang2 Zybody - Drug Profile 120
20(OH)D3 - Drug Profile 121
CIIF-4 - Drug Profile 122
OA-1 - Drug Profile 123
VLA-4 Antagonists - Drug Profile 124
Mesenchymal Stem Cells - Drug Profile 125
TLC-599 - Drug Profile 126
GB-88 - Drug Profile 127
Monolonal Antibody To Inhibit CCL20 For Arthritis And Contact Hypersensitivity - Drug Profile 128
S100-A8 - Drug Profile 129
CM-3457 - Drug Profile 130
Drug For Arthritis - Drug Profile 131
SYK Inhibitor - Drug Profile 132
ADAMTS-5 Inhibitor - Drug Profile 133
WIP-901C - Drug Profile 134
Nonimmunosuppressive Cyclosporin Analog Molecule Program - Drug Profile 135
Matrix Metalloproteinase Inhibitors for Cardiovascular, Musculoskeletal, Oncology and Immunology diseases - Drug Profile 137
Drug Targeting Subtype Selective G Protein Coupled Receptor - Drug Profile 138
OPK-30020 - Drug Profile 139
Drug For Chronic Inflammatory Diseases - Drug Profile 140
OPK-13031 - Drug Profile 141
Fibrin Blocking Peptides - Drug Profile 142
Peptide Antagonists - Drug Profile 143
EMMPRIN-Conjugates - Drug Profile 144
BMP-2 Modulators - Drug Profile 145
CD-99 Inhibitors - Drug Profile 146
FIV-based siRNA - Drug Profile 147
IBPB-001-PH - Drug Profile 148
Arthritis - Recent Pipeline Updates 149
Arthritis - Dormant Projects 161
Arthritis - Discontinued Products 162
Arthritis - Product Development Milestones 163
Featured News and Press Releases 163
Appendix 170
Methodology 170
Coverage 170
Secondary Research 170
Primary Research 170
Expert Panel Validation 170
Contact Us 171
Disclaimer 171

List of Tables

Number of Products under Development for Arthritis, H1 2014 14
Number of Products under Development for Arthritis - Comparative Analysis, H1 2014 15
Number of Products under Development by Companies, H1 2014 17
Number of Products under Development by Companies, H1 2014 (Contd..1) 18
Number of Products under Development by Companies, H1 2014 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H1 2014 21
Comparative Analysis by Clinical Stage Development, H1 2014 22
Comparative Analysis by Early Stage Development, H1 2014 23
Comparative Analysis by Unknown Stage Development, H1 2014 24
Products under Development by Companies, H1 2014 25
Products under Development by Companies, H1 2014 (Contd..1) 26
Products under Development by Companies, H1 2014 (Contd..2) 27
Products under Investigation by Universities/Institutes, H1 2014 28
Arthritis - Pipeline by Bristol-Myers Squibb Company, H1 2014 29
Arthritis - Pipeline by AstraZeneca PLC, H1 2014 30
Arthritis - Pipeline by GlaxoSmithKline plc, H1 2014 31
Arthritis - Pipeline by Taisho Pharmaceutical Co., Ltd., H1 2014 32
Arthritis - Pipeline by Sylentis S.A., H1 2014 33
Arthritis - Pipeline by Astellas Pharma Inc., H1 2014 34
Arthritis - Pipeline by Eisai Co., Ltd., H1 2014 35
Arthritis - Pipeline by Elan Corporation, plc, H1 2014 36
Arthritis - Pipeline by Teva Pharmaceutical Industries Limited, H1 2014 37
Arthritis - Pipeline by TheraKine Ltd., H1 2014 38
Arthritis - Pipeline by Bone Medical Limited, H1 2014 39
Arthritis - Pipeline by Can-Fite BioPharma Ltd., H1 2014 40
Arthritis - Pipeline by MEI Pharma, Inc., H1 2014 41
Arthritis - Pipeline by Lexicon Pharmaceuticals, Inc., H1 2014 42
Arthritis - Pipeline by CSL Limited, H1 2014 43
Arthritis - Pipeline by WhanIn Pharmaceutical Co., Ltd., H1 2014 44
Arthritis - Pipeline by Oscotec Inc., H1 2014 45
Arthritis - Pipeline by Viron Therapeutics, Inc., H1 2014 46
Arthritis - Pipeline by PLx Pharma Inc., H1 2014 47
Arthritis - Pipeline by Endocyte, Inc., H1 2014 48
Arthritis - Pipeline by Taiwan Liposome Company, Ltd., H1 2014 49
Arthritis - Pipeline by NasVax Ltd., H1 2014 50
Arthritis - Pipeline by Georgia Tech Research Corporation, H1 2014 51
Arthritis - Pipeline by CalciMedica, Inc., H1 2014 52
Arthritis - Pipeline by Zyngenia, Inc., H1 2014 53
Arthritis - Pipeline by SelectX Pharmaceuticals, Inc., H1 2014 54
Arthritis - Pipeline by AngioLab, Inc., H1 2014 55
Arthritis - Pipeline by DoNatur GmbH, H1 2014 56
Arthritis - Pipeline by PharmaIN Corporation, H1 2014 57
Arthritis - Pipeline by CellAct Pharma GmbH, H1 2014 58
Arthritis - Pipeline by LegoChem Biosciences, Inc, H1 2014 59
Arthritis - Pipeline by Ampio Pharmaceuticals, Inc., H1 2014 60
Arthritis - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2014 61
Arthritis - Pipeline by Sagene Pharmaceuticals, Inc., H1 2014 62
Arthritis - Pipeline by AnaMar AB, H1 2014 63
Arthritis - Pipeline by vida therapeutics inc., H1 2014 64
Arthritis - Pipeline by Aurinia Pharmaceuticals Inc., H1 2014 65
Arthritis - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2014 66
Assessment by Monotherapy Products, H1 2014 67
Assessment by Combination Products, H1 2014 68
Number of Products by Stage and Target, H1 2014 71
Number of Products by Stage and Mechanism of Action, H1 2014 75
Number of Products by Stage and Route of Administration, H1 2014 78
Number of Products by Stage and Molecule Type, H1 2014 81
Arthritis Therapeutics - Recent Pipeline Updates, H1 2014 153
Arthritis - Dormant Projects, H1 2014 165
Arthritis - Discontinued Products, H1 2014 166

List of Figures
Number of Products under Development for Arthritis, H1 2014 14
Number of Products under Development for Arthritis - Comparative Analysis, H1 2014 15
Number of Products under Development by Companies, H1 2014 16
Number of Products under Investigation by Universities/Institutes, H1 2014 20
Comparative Analysis by Clinical Stage Development, H1 2014 22
Comparative Analysis by Early Stage Products, H1 2014 23
Assessment by Monotherapy Products, H1 2014 67
Number of Products by Top 10 Target, H1 2014 69
Number of Products by Stage and Top 10 Target, H1 2014 70
Number of Products by Top 10 Mechanism of Action, H1 2014 73
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 74
Number of Products by Top 10 Route of Administration, H1 2014 77
Number of Products by Stage and Top 10 Route of Administration, H1 2014 78
Number of Products by Top 10 Molecule Type, H1 2014 79
Number of Products by Stage and Top 10 Molecule Type, H1 2014 80

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Scleroderma Diagnostics and Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Scleroderma Diagnostics and Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • November 2016
  • by Transparency Market Research

Global Scleroderma Diagnostics and Therapeutics Market: Overview Scleroderma, a very rare autoimmune disorder of the skin, is a term coined from the Greek words “sklerosis,” which means hardness, and ...

Phototherapy Equipment Market by Type, Application, End-user, Geography - Global Forecast to 2021

Phototherapy Equipment Market by Type, Application, End-user, Geography - Global Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global phototherapy equipment market is projected to reach USD 583.4 million by 2021, growing at a CAGR of 4.5% during the forecast period of 2016 to 2021. This market is primarily driven by the huge ...

Antinuclear Antibody Test Market by Product, Technique, Disease, End User - Forecast to 2021

Antinuclear Antibody Test Market by Product, Technique, Disease, End User - Forecast to 2021

  • $ 5650
  • Industry report
  • September 2016
  • by MarketsandMarkets

The global antinuclear antibody (ANA) testing market is expected to reach USD 1,476.1 million by 2021 from USD 823.5 million in 2016, at a CAGR of 12.4%. The global ANA testing market is segmented based ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.